‘Sleeping blockbuster’: MPM leads $53M Series E for Antiva as biotech seeks second go at tackling HPV
Antiva Biosciences has picked up another $53 million to bankroll two key studies of its topical drug for high-risk HPV infections and pre-cancerous lesions.
The decade-old South San Francisco biotech will test ABI-2280 in a global Phase II clinical trial in high-grade precancerous cervical lesions — known as cervical intraepithelial neoplasia (CIN 2,3) — and run an exploratory study to see if it can be a treatment for high-risk HPV infection.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.